advertisement
Humphries P 23
Showing records 1 to 23 | Display all abstracts from Humphries P108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
O'Callaghan J
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Chadderton N
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Delaney C
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Palfi A
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
O'Connor M
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Maloney DM
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
van Batenburg-Sherwood J
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Carrigan M
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
van Batenburg-Sherwood J; Schicht M
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Finnegan LK
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Lütjen-Drecoll E
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Hanlon KS
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Hudson N
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Shortall C; O'Reilly M
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Ni Dhubhghaill S
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Humphries P
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Humphries P; Stanley C
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Cassidy L; Kenna PF
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Keravala A
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Millington-Ward S
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Chalberg T
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Farrar GJ
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Lawrence MS; Campbell M
Science advances 2023; 9: eadf6537
